Evidence map›Paper›PMID 32378360›Full record

ArticlePharmacology research & perspectives2020

The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia.

Fatima Maqoud, Nicola Zizzo, Antonietta Mele, Nunzio Denora, Giuseppe Passantino, Rosa Scala, Annalisa Cutrignelli, Antonella Tinelli, Valentino Laquintana, Flavia la Forgia and 4 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Pharmacology research & perspectives, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Relevance of topical application of minoxidil laden nano-lipid for hair growth enhancement.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Fatima MaqoudSection of Pharmacology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Nicola ZizzoAnatomy Pathology, Department of Veterinary Medicine, University of Bari, Bari, Italy.
Antonietta MeleSection of Pharmacology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Nunzio DenoraPharmaceutical Technology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Giuseppe PassantinoAnatomy Pathology, Department of Veterinary Medicine, University of Bari, Bari, Italy.ORCID 0000-0002-6461-3434
Rosa ScalaSection of Pharmacology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Annalisa CutrignelliPharmaceutical Technology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Antonella TinelliAnatomy Pathology, Department of Veterinary Medicine, University of Bari, Bari, Italy.
Valentino LaquintanaPharmaceutical Technology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Flavia la ForgiaFarmalabor s.r.I., Centro di Ricerca "Dr. Sergio Fontana 1900-1982", Canosa di Puglia, Italy.
Sergio FontanaFarmalabor s.r.I., Centro di Ricerca "Dr. Sergio Fontana 1900-1982", Canosa di Puglia, Italy.
Massimo FrancoPharmaceutical Technology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Angela Assunta LopedotaPharmaceutical Technology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.
Domenico TricaricoSection of Pharmacology, Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Bari, Italy.ORCID 0000-0003-2726-0462
University of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of minoxidil (MXD) ethanolic solutions (1%-5% w/v) in the treatment of androgenetic alopecia is limited by adverse reactions. The toxicological effects of repeated topical applications of escalating dose (0.035%-3.5% w/v) and of single and twice daily doses (3.5% w/v) of a novel hydroxypropyl-β-cyclodextrin MXD GEL formulation (MXD/HP-β-CD) and a MXD solution were investigated in male rats. The cardiovascular effects were evaluated by telemetric monitoring of ECG and arterial pressure in free-moving rats. Ultrasonographic evaluation of cardiac morphology and function, and histopathological and biochemical analysis of the tissues, were performed. A pharmacovigilance investigation was undertaken using the EudraVigilance database for the evaluation of the potential cancer-related effects of topical MXD. Following the application of repeated escalating doses of MXD solution, cardiac hypertrophy, hypotension, enhanced serum natriuretic peptides and K

Indexed as

2-Hydroxypropyl-beta-cyclodextrinAdministration, TopicalAlopeciaAnimalsBlood PressureElectrocardiographyExcipientsFemaleGelsHumansMaleMinoxidilNeoplasmsPharmaceutical SolutionsPharmacovigilanceRats2-Hydroxypropyl-beta-cyclodextrinExcipientsGelsMinoxidilPharmaceutical Solutionsandrogenic alopeciaATP-sensitive potassium channelscell proliferationminoxidiltoxicology

Identifiers

PMID32378360
PMCPMC7203570
OpenAlexW3022860738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.